|Bid||74.56 x 4000|
|Ask||76.28 x 1800|
|Day's Range||74.78 - 76.86|
|52 Week Range||37.36 - 80.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||84.70|
Exact Sciences (EXAS) stock has reported a 67.1% rise in the last month, from $49.93 on August 10 to $75.99 on September 10. Its performance was mainly due to its collaboration with Pfizer (PFE) for the increasing adoption of Exact Sciences’ Cologuard non-invasive stool DNA test for colorectal cancer screening in the United States. According to the collaboration announced on August 22, Pfizer will actively participate in promoting Cologuard until 2021.
MADISON, Wis., Aug. 31, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences during September and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.
NEW YORK, NY / ACCESSWIRE / August 24, 2018 / U.S. markets plunged on Thursday following the release of the minutes from the latest Federal Reserve meeting, which called for an interest hike in September. ...
Exact Sciences (NASDAQ:EXAS) shares have bolted above both their 50-day and 200-day moving averages, rising nearly 30% in mid-day trading on Wednesday to return to the upper end of a three-month trading range. The company will next report results on Oct. 31, after the bell. When the company last reported on Aug. 1, a loss of 30-cents-per-share beat estimates by 3 cents on a 79% rise in revenues on a year-over-year basis.
Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Exact Sciences made headlines on Wednesday, announcing an agreement with Pfizer to share marketing expenses and to co-promote the company’s Colorguard colorectal ...
Stocks that moved substantially or traded heavily Wednesday: Target Corp., up $2.67 to $85.94 The retailer raised its annual forecasts as its sales over the internet and in stores both climbed. Lowe's ...
Global pharmaceutical company Pfizer Inc. has entered into a four-year agreement with Exact Sciences Corp. to co-promote and sell the Madison company's noninvasive stool DNA-based colorectal cancer take-home test in the United States. Under the terms of the agreement, which runs through December of 2021, the companies will form a joint committee that will approve marketing plans and marketing budgets and will invest $174 million in the marketing and and promotion of Cologuard over the next four years. Exact Sciences must maintain its originally planned commitment to spend $80 million in each of the four years on out-of-pocket marketing and promotional material.
Exact Sciences doesn’t do glamorous work, but on Wednesday its shareholders got beautiful results. The health-care company announced a collaboration deal with Pfizer to market its signature product, Cologuard, a stool DNA screening test for colorectal cancer.
On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.
Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer. The companies will invest a combined $48 million, shared equally, next year to market the non-invasive DNA screening test Cologuard, Exact Sciences Chief Executive Officer Kevin Conroy told Reuters in an interview. "The marketing effort will begin in the fourth quarter (and) we expect the impact (of it) to occur next year," Conroy said, adding that the company is currently investing about $80 million in advertising and promoting Cologuard.
Exact Sciences Corp. shares (exas) soared about 11% in premarket trade Wednesday, after the company said it will collaborate with Pfizer Inc. (pfe) in co-promoting Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer, through 2021. As part of the deal, Pfizer will join Exact Sciences' sales reps in targeting doctors and health systems and help market the test. Colorectal cancer is the second leading cause of cancer death in the U.S. with more than 50,000 deaths a year.
MADISON, Wis., Aug. 22, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will host a conference call and webcast on Wednesday, Aug. 22, 2018, at 8:00 a.m. ET to discuss details of its co-promotion agreement with Pfizer. Nick Lagunowich, regional president North America, Pfizer Internal Medicine, will also make remarks on the call. The webcast will be available at www.exactsciences.com.
MADISON, Wis. and NEW YORK, Aug. 22, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) and Pfizer Inc. (PFE) today announced an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer. Colorectal cancer is recognized as the most preventable yet least prevented form of cancer and remains the second leading cause of cancer death in the U.S., with more than 50,000 deaths each year. Nine out of 10 people survive more than five years when colorectal cancer is diagnosed in Stages I or II, but only one out of 10 people survive more than five years when the disease is diagnosed in Stage IV.
Jim Cramer chats with Exact Sciences' CEO Kevin Conroy about the company's new partnership with Pfizer and its long-term goals.
Let's check out the Yahoo Finance charts of the day. Target (TGT): Shares are up in early trade, at around 5.3%. The retailer saw a 6.4% increase in traffic growth, the strongest number its posted since they started reporting traffic in 2008. It also announced comparable sales growth of 6.5% which is the largest increase in 13 years. La-Z-Boy (LZB): Shares are up here, at around 13.9%. The furniture retailer beat estimates by 9 cents a share, with adjusted quarterly profit of 34 cents per share. The company's revenue also topped forecasts. Increased sales of higher-priced furniture helped La-Z-Boy's results. Exact Sciences (EXAS): Shares up here, at around 21.8%. Exact Sciences struck a deal with Pfizer for its Cologuard product, a non-invasive in-home screening test for colorectal cancer. For more on today's big stock movers check out the Final Round, live at 3:30 p.m. ET, right here on Yahoo Finance.